About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker LLY · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3C…
NCT07935317 · Breast Neoplasms
Abemaciclib, Tersolisib
LLY
Eli Lilly and Company
Phase 2Not yet recruiting120Dec 2027Registry ↗
Nov 13, 2026A Study Assessing Eloralintide (LY3841136) in Healthy Participants
NCT07935304 · Healthy
Eloralintide, Eloralintide
LLY
Eli Lilly and Company
Phase 1Not yet recruiting90Apr 2027Registry ↗
Nov 13, 2026A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
NCT07883590 · Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme Syst…
LY3873862, CYP450 Drug Cocktail
LLY
Eli Lilly and Company
Phase 1Not yet recruiting32Nov 2027Registry ↗
Nov 13, 2026Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Se…
NCT06297603 · Type 2 Diabetes
Retatrutide, Placebo
LLY
Eli Lilly and Company
Phase 3Active, not recruiting320Oct 26, 2026Registry ↗
Nov 12, 2026A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923 · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
LY4175408, Pembrolizumab
LLY
Eli Lilly and Company
Phase 1Active, not recruiting
was recruiting
240Jul 2030Registry ↗
Nov 12, 2026A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
NCT06220669 · Multiple Sclerosis
LY3541860, Placebo
LLY
Eli Lilly and Company
Phase 2Terminated65Oct 18, 2025Registry ↗
Nov 12, 2026A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesi…
NCT05556512 · Obesity, Overweight
Tirzepatide, Placebo
LLY
Eli Lilly and Company
Phase 3Active, not recruiting15,374Oct 2027Registry ↗
Nov 12, 2026A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type…
NCT05433584 · Type 2 Diabetes
Tirzepatide, Antihyperglycemic medication
LLY
Eli Lilly and Company
Phase 4Active, not recruiting794Oct 21, 2025Registry ↗
Nov 10, 2026A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258 · Endometrial Neoplasms, Ovarian Neoplasms
LY4336619, Sofetabart Mipitecan (Sofe-M)
LLY
Eli Lilly and Company
Phase 1Not yet recruiting370Mar 2032Registry ↗
Nov 10, 2026A Study of Brenipatide in Participants With Major Depressive Disorder
NCT07928245 · Major Depressive Disorder
Brenipatide, Placebo
LLY
Eli Lilly and Company
Phase 2Not yet recruiting330May 2028Registry ↗
Nov 10, 2026A Study of LY3981314 in Participants With Autoimmune Hepatitis
NCT07928219 · Hepatitis Autoimmune Disease, Hepatitis
LY3981314
LLY
Eli Lilly and Company
Phase 1Not yet recruiting12Jun 2028Registry ↗
Nov 10, 2026A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719 · Obesity, Overweight
Retatrutide, Placebo
LLY
Eli Lilly and Company
Phase 3Active, not recruiting250Jun 2027Registry ↗
Nov 10, 2026A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685 · Metastatic Solid Tumor, Advanced Solid Tumor
LY4050784, Pembrolizumab
LLY
Eli Lilly and Company
Phase 1Active, not recruiting
was recruiting
340Oct 2027Registry ↗
Nov 9, 2026A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
NCT07232732 · Healthy, Obesity
LY3549492
LLY
Eli Lilly and Company
Phase 1Completed120Jul 17, 2026Registry ↗
Nov 9, 2026A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and…
NCT05936151 · Overweight or Obesity, CKD
Retatrutide, Placebo
LLY
Eli Lilly and Company
Phase 2Completed146Oct 1, 2025Registry ↗
Nov 6, 2026A Study of Bimagrumab in Participants With HFpEF
NCT07920887 · Heart Failure, Diastolic, Diastolic Heart Failure
Bimagrumab, Placebo
LLY
Eli Lilly and Company
Phase 2Not yet recruiting540Jul 2029Registry ↗
Nov 6, 2026A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
NCT07258836 · Neoplasms, Healthy
LY4214835
LLY
Eli Lilly and Company
Phase 1Recruiting41Dec 2027Registry ↗
Nov 5, 2026A Study of Imlunestrant (LY3484356) in Healthy Female Participants
NCT07918859 · Healthy
Imlunestrant (Test), Imlunestrant (Reference)
LLY
Eli Lilly and Company
Phase 1Not yet recruiting343Aug 2027Registry ↗
Nov 5, 2026A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related C…
NCT07794579 · Overweight, Prediabetic State
Orforglipron, Placebo
LLY
Eli Lilly and Company
Phase 3Recruiting2,001Aug 2029Registry ↗
Nov 5, 2026A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Partici…
NCT07787169 · Alzheimer Disease, Amyloid
LY4405094, LY4405094
LLY
Eli Lilly and Company
Phase 1Recruiting179Jul 2028Registry ↗
Nov 5, 2026A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructiv…
NCT07759245 · Pulmonary Disease, Chronic Obstructive
Brenipatide, Placebo
LLY
Eli Lilly and Company
Phase 2Recruiting606May 2028Registry ↗
Nov 5, 2026A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2…
NCT07668336 · Diabetes Mellitus, Type 2
Orforglipron, Dulaglutide
LLY
Eli Lilly and Company
Phase 3Recruiting170Mar 2030Registry ↗
Nov 5, 2026A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-…
NCT07545772 · Irritable Bowel Syndrome, Constipation
LY3537031, Placebo
LLY
Eli Lilly and Company
Phase 2Recruiting342Jul 2027Registry ↗
Nov 5, 2026A Study of LY4515100 in Healthy Participants
NCT07339722 · Healthy
LY4515100 via SAD, LY4515100 via MAD
LLY
Eli Lilly and Company
Phase 1Recruiting209Mar 2027Registry ↗
Nov 5, 2026A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moder…
NCT07219173 · Asthma
Brenipatide, Brenipatide
LLY
Eli Lilly and Company
Phase 2Recruiting531Apr 2028Registry ↗
Nov 5, 2026A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07100119 · ALS (Amyotrophic Lateral Sclerosis)
LY4256984, Placebo
LLY
Eli Lilly and Company
Phase 1Recruiting36Aug 2027Registry ↗
Nov 5, 2026A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participa…
NCT05986292 · Osteoarthritis, Knee, Diabetic Neuropathic Pain
LY3016859 ISA, LY3556050 ISA
LLY
Eli Lilly and Company
Phase 2Recruiting10,000Apr 2027Registry ↗
Nov 4, 2026A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy
NCT07915245 · Obesity, Overweight
LY4247147, LY4247147
LLY
Eli Lilly and Company
Phase 1Not yet recruiting108Oct 2028Registry ↗
Nov 4, 2026A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)
NCT07914738 · Lipoprotein(a)
LY3819469
LLY
Eli Lilly and Company
Phase 1Not yet recruiting66Mar 2027Registry ↗
Nov 4, 2026A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT07881458 · Obesity, Overweight
eloralintide and tirzepatide, Tirzepatide
LLY
Eli Lilly and Company
Phase 3Recruiting
was not yet recruiting
1,000Oct 2029Registry ↗
Nov 4, 2026Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Ped…
NCT07817875 · Obesity
Tirzepatide, Placebo
LLY
Eli Lilly and Company
Phase 3Recruiting150Dec 2029Registry ↗
Nov 4, 2026A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain
NCT07641517 · Osteoarthritis, Knee, Chronic Pain
LY4065967, Placebo
LLY
Eli Lilly and Company
Phase 2Recruiting150Apr 2027Registry ↗
Nov 4, 2026A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back P…
NCT07641504 · Chronic Pain, Low Back Pain
LY4065967, Placebo
LLY
Eli Lilly and Company
Phase 2Recruiting150Apr 2027Registry ↗
Nov 4, 2026A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a)…
NCT07613294 · Atherosclerosis, Cardiovascular Diseases
Lepodisiran, Placebo
LLY
Eli Lilly and Company
Phase 3Recruiting252Dec 2029Registry ↗
Nov 4, 2026A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizuma…
NCT07612267 · Lactation, Inflammatory Bowel Disease
Mirikizumab
LLY
Eli Lilly and Company
Phase 4Recruiting14Sep 2028Registry ↗
Nov 4, 2026A Study of LY3439539 in Participants With Alzheimer's Disease
NCT07598370 · Alzheimer Disease
LY3439539
LLY
Eli Lilly and Company
Phase 1Recruiting30Aug 2027Registry ↗
Nov 4, 2026A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595 · Cognitive Dysfunction, Lewy Body Disease
Donanemab, Placebo
LLY
Eli Lilly and Company
Phase 2Recruiting350Aug 2028Registry ↗
Nov 4, 2026A Study of LY3971297 in Participants With Heart Failure
NCT07547540 · Heart Failure, Heart Failure, Diastolic
LY3971297, LY3971297
LLY
Eli Lilly and Company
Phase 1Recruiting90Nov 2027Registry ↗
Nov 4, 2026A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759 · Irritable Bowel Syndrome, Diarrhea
LY3537031, Placebo
LLY
Eli Lilly and Company
Phase 2Recruiting531Sep 2027Registry ↗
Nov 4, 2026A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019 · Vitiligo, Non-Segmental Vitiligo (NSV)
LY4005130, Placebo
LLY
Eli Lilly and Company
Phase 2Recruiting66May 2027Registry ↗
Nov 4, 2026A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT07533006 · Alopecia Areata
LY4005130, Placebo
LLY
Eli Lilly and Company
Phase 2Recruiting65Jun 2027Registry ↗
Nov 4, 2026Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
NCT07503613 · Vestibular Schwannoma
LLY
Eli Lilly and Company
—Enrolling by invitation100Apr 2040Registry ↗
Nov 4, 2026A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults W…
NCT07483099 · Crohn Disease
LY4395089, Mirikizumab - Intravenous (IV)
LLY
Eli Lilly and Company
Phase 2Recruiting60Jun 2027Registry ↗
Nov 4, 2026A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Di…
NCT07483073 · Colitis, Ulcerative, Crohn Disease
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous…
LLY
Eli Lilly and Company
Phase 2Recruiting60Jun 2027Registry ↗
Nov 4, 2026A Study of Brenipatide in Participants With Opioid Use Disorder
NCT07420283 · Opioid Use Disorder
Brenipatide, Placebo
LLY
Eli Lilly and Company
Phase 2Recruiting465Mar 2028Registry ↗
Nov 4, 2026LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044 · Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
LY4268989, Placebo
LLY
Eli Lilly and Company
Phase 2Recruiting1,431Jun 2030Registry ↗
Nov 4, 2026A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756 · Depressive Disorder, Major
Brenipatide, Placebo
LLY
Eli Lilly and Company
Phase 3Recruiting1,000Feb 2028Registry ↗
Nov 4, 2026A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a…
NCT07392190 · Overweight, Obesity
Eloralintide, Placebo
LLY
Eli Lilly and Company
Phase 3Recruiting900Jun 2028Registry ↗
Nov 4, 2026A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Ove…
NCT07369011 · Sleep Apnea, Obstructive, Obesity
Eloralintide, Placebo
LLY
Eli Lilly and Company
Phase 3Recruiting800Mar 2028Registry ↗
Nov 4, 2026Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and O…
NCT07353931 · Osteoarthritis, Overweight or Obesity
Eloralintide, Placebo
LLY
Eli Lilly and Company
Phase 3Recruiting900Mar 2028Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:18 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances